Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352672 | 0.85 | MAOA (0.61) | MAOAMAOBTAAR1SLC6A3SLC6A4 | |
| SCHEMBL3155718 | 0.84 | OPRM1 (0.51) | OPRM1MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL5166600 | 0.84 | SLC6A4 (0.64) | OPRM1MCHR1MAOAMAOBTAAR1 | |
| SCHEMBL4656331 | 0.84 | SLC6A3 (0.64) | OPRM1MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL468959 | 0.84 | MAOA (0.68) | OPRM1MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3597198 | 0.82 | MAOA (0.66) | OPRM1MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL17888243 | 0.82 | OPRM1 (0.50) | OPRM1MCHR1SLC6A3P2RX7 | |
| SCHEMBL19220899 | 0.81 | GRIN2D (0.47) | OPRM1MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL5166711 | 0.81 | CHRM5 (0.48) | MAOAMAOBTAAR1SLC6A4DPP4 | |
| SCHEMBL8353188 | 0.81 | DPP4 (0.59) | MAOAMAOBTAAR1SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | OPRM1 1787/4885MCHR1 4169/4885MAOA 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.